When a meta-analysis is unhelpful: if the included studies are heterogeneous in population, intervention, or outcome, pooling them produces a number that represents nothing in particular. Reading the individual studies is more useful than reading the pooled estimate.
Pooling trials with different estimands posts 121–133
This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1 · go to the accepted answer.
Pooled estimates and heterogeneity: when trials differ in population, duration, or comparator, a pooled estimate answers a question that no individual trial asked. High heterogeneity means effects genuinely differ across studies. The pooled number is an average of things that should not have been averaged.
I read post #121 twice before replying, because I had assumed the opposite.
Publication bias: what did not get published? Small studies with negative results are less likely to be published than large studies with positive results. A forest plot with only large studies on the positive end is a red flag for unpublished small negative studies.
This follows post #121 rather than contradicting it.
Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the kind that comes from remembering a figure instead of looking it up.
On post #121 — agreed on the reasoning, with one qualification.
Number needed to treat from a meta-analysis: can be computed from the pooled estimate if the baseline risk is specified. More interpretable than pooled relative effects.
Subgroup analysis: sometimes a meta-analysis reports separate pooled estimates for different subgroups (e.g., by baseline body mass index or by trial duration). Be cautious — many subgroup analyses are exploratory and less reliable than the main analysis.
Picking up post #125: that is the part I would want checked first.
Pooled estimates and heterogeneity: when trials differ in population, duration, or comparator, a pooled estimate answers a question that no individual trial asked. High heterogeneity means effects genuinely differ across studies. The pooled number is an average of things that should not have been averaged.
Publication bias: what did not get published? Small studies with negative results are less likely to be published than large studies with positive results. A forest plot with only large studies on the positive end is a red flag for unpublished small negative studies.
post #129 is right about the mechanism and I think understates the practical bit.
Why forest plots are more informative than pooled numbers: they show the variation across studies, which tells you whether the effect is consistent or heterogeneous. A narrow confidence interval around a meaningless centre is less useful than a wider interval that shows real differences.
Funnel plots: a plot of study effect size versus sample size that helps detect publication bias. If small studies are missing on the negative side, the funnel is asymmetrical.
Collapsed as off-topic by two members at trust level 3 or above
Study quality and weighting: some meta-analyses weight all studies equally; others weight by study size or study quality. The choice affects the result and should be stated and justified.
post #132 is right about the mechanism and I think understates the practical bit.
For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.
Suggested topics
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Individual participant data versus aggregate data
Posting this under the heading it deserves: Individual participant data versus aggregate data Everything below is what sits behind that. Session topic: SCALE ( N Engl J Med , 2015). Please read it before…
|
+30 | 34 | 64k | 14mo |
|
Pooling trials with different estimands — what changed since
Pooling trials with different estimands — what changed since — setting out what I have, and where I think it stops being reliable. Comparing STEP 4 ( JAMA , 2021) with SURPASS-4 ( Lancet , 2021) and finding…
|
+57 | 64 | 12k | 7mo |
|
Follow-up: Individual participant data versus aggregate data
Individual participant data versus aggregate data — setting out what I have, and where I think it stops being reliable. Comparing LEADER ( N Engl J Med , 2016) with SURPASS-4 ( Lancet , 2021) and finding the…
|
+101 | 111 | 23k | 18mo |
|
Random versus fixed effects: choosing rather than defaulting
Random versus fixed effects: choosing rather than defaulting — setting out what I have, and where I think it stops being reliable. Session topic: FLOW ( N Engl J Med , 2024). Please read it before posting;…
|
+16 | 20 | 22k | 13mo |
|
When a network meta-analysis is defensible and when it is not
When a network meta-analysis is defensible and when it is not I have a specific reason for asking rather than idle curiosity, and the context is below. Comparing SUSTAIN 6 ( N Engl J Med , 2016) with LEADER (…
|
2 | 27k | 4h |
Related topics — sharing the tags publication bias, risk of bias, effect size
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Is there a ceiling dose beyond which semaglutide stops adding benefit?
Is there a ceiling dose beyond which semaglutide stops adding benefit? I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SURPASS-4 ( Lancet , 2021) cited in…
|
2 | 14k | 2mo | |
|
Pooling trials with different estimands — what changed since
Pooling trials with different estimands — what changed since — setting out what I have, and where I think it stops being reliable. Comparing STEP 4 ( JAMA , 2021) with SURPASS-4 ( Lancet , 2021) and finding…
|
+57 | 64 | 12k | 7mo |
|
Follow-up: What is genuinely unknown about long-term amylin agonism
What is genuinely unknown about long-term amylin agonism I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SUSTAIN 6 ( N Engl J Med , 2016) cited in support…
|
2 | 25k | 11mo | |
|
Citing a preprint in a maintained document: our rule and its reasoning
On the subject in the title: Citing a preprint in a maintained document: our rule and its reasoning Working notes rather than a conclusion. I have seen SELECT ( N Engl J Med , 2023) cited in support of a…
|
2 | 467 | 4mo | |
|
What TRIUMPH is designed to answer, and why we should not pre-empt it — does this still hold?
Asking directly, because I could not find a straight answer: What TRIUMPH is designed to answer, and why we should not pre-empt it — does this still hold? Session topic: STEP 2 ( Lancet , 2021). Please read…
|
+43 | 47 | 5.5k | just now |